EP1204409A1 - Microparticules pour administration pulmonaire - Google Patents
Microparticules pour administration pulmonaireInfo
- Publication number
- EP1204409A1 EP1204409A1 EP00958655A EP00958655A EP1204409A1 EP 1204409 A1 EP1204409 A1 EP 1204409A1 EP 00958655 A EP00958655 A EP 00958655A EP 00958655 A EP00958655 A EP 00958655A EP 1204409 A1 EP1204409 A1 EP 1204409A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- coating agent
- fluid
- active principle
- poly
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Definitions
- the present invention relates to the field of microparticles intended to be administered by the pulmonary route.
- Aerosols for the release of therapeutic agents into the respiratory tract have been described, for example (Adjei, A. and Garren, J. Pharm. Res., 7: 565-569 (1990); and Zanen, P. and Lamm, JWJ Int. J. Pharm., 114: 111-115 (1995)).
- the respiratory tract includes the upper respiratory tract which includes the larynx and the oropharynx, and the lower respiratory tract including the trachea which continues in bifurcations: the bronchi and bronchioles.
- the terminal bronchioles are then divided into respiratory bronchioles which lead to the ultimate zone of the respiratory system, the pulmonary alveoli also called the deep lung (Gonda, I.
- Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract are the main target of therapeutic inhalation aerosols intended for the systemic route. Aerosols intended for inhalation have already been used for the treatment of local pulmonary disorders such as asthma and cystic fibrosis (Anderson et al., Am. Rev. Respir. Dis., 140: 1317-1324 (1989)) . In addition, they can be used for the systemic release of peptides and proteins (Patton and Platz, Advanced Drug Delivery Reviews, 8: 179-196 (1992)).
- the human lung can quickly eliminate or degrade hydrolysable products deposited in the form of aerosols, this phenomenon generally takes place over a period of between a few minutes and a few hours.
- the ciliated epithelium contributes to the “mucociliary escalator” phenomenon by which particles are entrained from the pulmonary tract to the mouth (Pavia, D. “Lung Mucociliary Clearance,” in Aérosols and the Lung: Clinical and Experimental Aspects, Clarke, SW and Pavia, D., Eds., Butterworths, London, 1984.; Anderson et al., Am. Rev. Respir. Dis., 140: 1317-1324 (1989)).
- alveolar macrophages are able to phagocytose particles immediately after their deposition.
- Local and systemic inhalation therapies generally allow a controlled and relatively slow release of the active ingredient (Gonda, I., “Physico-chemical principles in aerosol delivery,” in: Topics in Pharmaceutical Sciences 1991, DJA Crommelin and KK Midha, Eds. , Stuttgart: Medpharm Scientific Publishers, pp. 95-117 (1992)).
- the slow release of the therapeutic aerosol can prolong the residence time of the drug administered in the pulmonary tract or in the acini and decrease the rate of entry of the drugs into the blood stream.
- microparticles which meet the criteria imposed by their applications under effective conditions.
- these microparticles In order to be sufficiently effective, these microparticles must not be damaged during administration, during their passage in nebulized form.
- the bioavailability of these microparticles must reach a sufficiently high value, or the bioavailability of the microparticles of the prior art generally does not exceed 50%, because of a low rate of deposition of the microparticles in the pulmonary alveolar regions.
- the microparticles, once deposited in the alveoli must be sufficiently stable in the mucosa of the surface of these alveoli.
- microparticles for immediate or delayed release generally have an outer layer whose thickness relative to the diameter of said particle is not negligible.
- microparticles according to the invention consist of a core containing the active material coated with a layer of coating agent deposited by the technique of supercritical fluid. This particular structure distinguishes them from the microparticles of the prior art which are matrix microspheres obtained by emulsion-solvent evaporation techniques, solvent extraction by aqueous phases or nebulization-drying of organic solution.
- the present invention relates to biocompatible microparticles intended to be inhaled comprising at least one active principle and at least one layer coating this active principle which is the outer layer of said microparticles, said outer layer containing at least one coating agent, said microparticles having an average diameter between 1 ⁇ m and 30 ⁇ m, an apparent density between 0.02 g / cm 3 and 0.8 g / cm 3 , and being capable of being obtained according to a process comprising the essential steps which are the setting in the presence of a coating agent with an active principle and the introduction of a supercritical fluid, with stirring in a closed reactor.
- These microparticles do not agglomerate when administered, and may possibly allow a prolonged release of the active principle.
- the microparticles according to the invention have a bioavailability greater than 60% and preferably greater than 80% thanks to an improvement in the rate of deposition of the particles in the alveolar pulmonary zones.
- the biocompatible microparticles intended for inhalation according to the invention have an external layer comprising a coating agent which prevents the aggregation of these particles between them.
- the coverage rate of the surface of the particles is at least greater than 50%, preferably greater than 70%, more preferably still greater than 85%.
- the quality of this coating is essentially due to the technique of supercritical fluid.
- Said method comprises two essential steps which are the placing in the presence of a coating agent with an active principle and the introduction of a supercritical fluid in order to ensure the coacervation of the coating agent.
- the first process for preparing the microparticles according to the invention differs from the second process in that the coating agent is at no time in solution in the fluid in the liquid or supercritical state.
- a first implementation of the method according to the invention comprises the following steps: suspending an active principle in a solution of at least one substantially polar coating agent in an organic solvent, said active principle being insoluble in the organic solvent, said substantially polar coating agent being insoluble in a fluid in the supercritical state, said organic solvent being soluble in a fluid in the supercritical state,
- the fluid used for the implementation of this first process is preferably liquid CO 2 or in the supercritical state.
- the organic solvent used for the implementation of this first process is generally chosen from the group consisting of ketones, alcohols and esters.
- the supercritical fluid is brought into contact with the suspension of active principle containing the coating agent in solution is carried out by introduction of the supercritical fluid into an autoclave already containing the suspension.
- the employee supercritical fluid is CO 2 can be used CO 2 in liquid form or directly to the CO 2 in the supercritical state.
- the suspension can also be brought into contact with liquid CO 2 which will then pass to the supercritical state by increasing the pressure and / or the temperature in the autoclave in order to extract the solvent.
- the temperature is preferably chosen between 20 and 30 ° C and the pressure between 80 and 150 10 5 Pa.
- the temperature is generally chosen between 35 and 60 ° C, preferably between 35 and 50 ° C, and the pressure between 80 and 250 10 5 Pa, preferably between 100 and 220 10 5 Pa.
- the mass of organic solvent introduced into the autoclave represents at least 3%, preferably between 3.5% and 25% of the mass of the supercritical fluid or liquid used to cause the desolvation of the coating agent.
- the microparticles obtained by the implementation of this first process have an outer layer almost free of solvent, the amount of solvent in the outer layer is indeed less than 500 ppm.
- the coating agents which can be used for the implementation of this first process are more particularly:
- biodegradable (co) polymers of ⁇ -hydroxycarboxylic acids in particular homopolymers and copolymers of lactic and glycolic acids, and more particularly PLA (Poly-L-lactide) and PLGA (Poly-Lactic-co-Glycolic-Acid) ,
- phospholipids such as phosphatidyl glycerols, diphosphatidyl glycerols with fatty acid chains from C12 to C18 (DLPG, DMPG, DPPG, DSPG), phosphatidylcholines, diphosphatidylcholines with fatty acid chains from C12 to C18 (DLPC, DMPC , DPPC, DSPC), diphosphatidyl ethanolamines with C12 to C18 fatty acid chains (DLPE, DMPE, DPPE, DSPE), diphosphatidyl serines with C12 to C18 chains (DLPS, DMPS, DPPS, DSPS), and mixtures which would contain the phospholipids mentioned,
- - fatty acid esters such as glyceryl stearates, glyceryl laurate, cetyl palmitate, or mixtures which contain these compounds,
- the implementation of the second method according to the invention consists in suspending an active principle in a supercritical fluid containing at least one coating agent dissolved in it, then in modifying the pressure and / or temperature conditions of the medium to ensure the coacervation of the particles, by precipitation of the coating agent around the particles of active principle, that is to say ensuring the coacervation of the particles by physico-chemical modification of the medium.
- the coating agents which can be used for the implementation of this second process are more particularly:
- phospholipids such as phosphatidyl glycerols, diphosphatidyl glycerols with fatty acid chains from C12 to C18 (DLPG, DMPG, DPPG, DSPG), phosphatidylcholines, diphosphatidylcholines with fatty acid chains from C12 to C18 (DLPC, DMPC , DPPC, DSPC), diphosphatidyl ethanolamines with C12 to C18 fatty acid chains (DLPE, DMPE, DPPE, DSPE), diphosphatidyl serines with C12 to C18 chains (DLPS, DMPS, DPPS, DSPS), and mixtures which would contain the phospholipids mentioned,
- fatty acid esters such as glyceryl stearates, glyceryl laurate, cetyl palmitate, - mixtures which would contain the compounds mentioned above.
- Biodegradable or bioerodible polymers soluble in a supercritical fluid can also be used in this second process.
- the coacervation (or aggregation) of a coating agent is caused by physicochemical modification of a medium containing an active substance in suspension in a solution of coating agent in a solvent, said solvent being a supercritical fluid.
- the supercritical fluid preferentially used is supercritical CO 2 (CO 2 SC), the initial operating conditions typical of this second process will be approximately 31 to 80 ° C. and the pressures from 75 to 250 10 5 Pa, although the higher values of either or both of the two parameters may be used, provided of course that the higher values have no harmful or degrading effect on the active ingredient during coating, nor on the coating agents. Furthermore, one can also choose other fluids commonly used as supercritical fluids.
- ethane which becomes supercritical above 32 ° C and 48 10 5 Pa
- nitrogen dioxide whose critical point is 36 ° C and 72 10 5 Pa
- propane whose critical point is of 96 ° C and 42 10 5 Pa
- trifluoromethane whose critical point is 26 ° C and 47 10 5 Pa
- chlorotrifluoromethane whose critical point is 29 ° C and 39 10 5 Pa.
- This second method involves suspending, in a closed and stirred autoclave, an active principle which is not soluble in the supercritical fluid, said supercritical fluid containing a coating agent which is in the solute state.
- the pressure and / or the temperature are then modified so as to reduce the solubility of the coating agent in the fluid.
- the affinity of the coating agent for the active principle increases so that this coating is adsorbed around the active principle.
- the active ingredient to be coated and the coating agent (s) are placed in an autoclave equipped with an agitator, then the system is pressurized by introducing a fluid into the autoclave under supercritical conditions. Then, the temperature and / or pressure inside the autoclave is modified in a controlled and regulated manner so as to gradually reduce the solubility of the coating agent (s). When the solubility of this or these coating agents in the supercritical fluid decreases, it (s) precipitates (s) and the affinity of these agents for the surface of the active principle leads to their adsorption on this surface.
- a variant of this process consists in placing the coating agent in the autoclave before introducing the active principle therein or by simultaneously introducing therein the active principle and a fluid capable of passing to the supercritical state. Pressurizing the autoclave to produce a state of supercritical fluid will then cause the coating agent to dissolve in said supercritical fluid.
- the active principle is placed in an autoclave equipped with an agitator
- the coating agent is placed in a second autoclave equipped with an agitator into which is introduced the fluid capable of passing to the supercritical state .
- the coating agent is brought into the solute state by increasing the temperature and the pressure, then is transferred to the autoclave where the active principle is located.
- the active principle can be in the form of a liquid which can thus form an emulsion in the supercritical fluid, of preformed solid particles, and in particular of microparticles possibly already coated for example with mono- or disaccharides.
- the stirring speeds can vary between 150 and 700 rpm for solid particles and between 600 and 1000 rpm when the active principle is a liquid. Such stirring ensures the suspension of the active principle in the supercritical fluid when the latter is introduced.
- the supercritical conditions are ensured by a modification of the temperature and / or the pressure inside the autoclave.
- the temperature of the autoclave is between 35 and 80 ° C, preferably between 35 and 50 ° C
- the pressure is between 100 and 250 10 5 Pa, and preferably between 180 and 220 10 5 Pa.
- the temperature of the autoclave is between 35 and 80 ° C, preferably between 35 and 50 ° C, and the pressure is between 50 and 200 10 5 Pa, and preferably between 50 and 150 10 5 Pa.
- the temperature of the autoclave is between 45 and 80 ° C, preferably between 55 and 65 ° C, and the pressure is between 40 and 150 10 5 Pa.
- the coating agent is introduced into the autoclave at the same time as the supercritical fluid or else before the introduction into the autoclave of the supercritical fluid.
- the system is kept in equilibrium with stirring, the appropriate concentration of active principle and coating agent is established as a function of the desired microparticles and the this balance under stirring for one hour.
- the temperature and the pressure are then modulated at a speed slow enough to completely transfer the coating agent (s) from the supercritical fluid to the surface of the active principle and the system is depressurized to isolate the microparticles which are removed from the autoclave.
- the microparticles according to the present invention have a diameter between 1 ⁇ m and 30 ⁇ m, preferably between 1 ⁇ m and 15 ⁇ m, and even more preferably between 2 ⁇ m and 10 ⁇ m and a bulk density between 0.02 g / cm 3 and 0.8 g / cm 3 and preferably between 0.05 g / cm 3 and 0.4 g / cm 3 .
- the active ingredient / coating agent mass ratio of these microparticles is preferably between 95/5 and 5/95.
- the mass ratio of active principle / coating agent is then between 5/95 and 20/80, on the contrary in the case where the coating is intended to stabilize the particle, in particular when the microparticle is in immediate release, the mass ratio active ingredient / coating agent is generally between 95/5 and 70/30 and preferably between 95/5 and 80/20.
- biodegradable (co) polymers of hydroxycarboxylic acids in particular homopolymers and copolymers of lactic and glycolic acids, and more particularly PLA (Poly-L-lactide) and PLGA (Poly-Lactic-co-Glycolic-Acid),
- phospholipids such as phosphatidyl glycerols, diphosphatidyl glycerols with fatty acid chains from C12 to C18 (DLPG, DMPG, DPPG, DSPG), phosphatidylcholines, diphosphatidylcholines with fatty acid chains from C12 to C18 (DLPC, DMPC, DPPC, DSPC), disphosphatidyl etanolamines with C12 to C18 fatty acid chains (DLPE, DMPE, DPPE, DSPE), diphosphatidyl serines with C12 to C18 chains (DLPS, DMPS, DPPS, DSPS ), and the mixtures which would contain the phospholipids mentioned,
- Said active principle can be in the form of a liquid, a solid powder or an inert porous solid particle comprising on its surface an active principle.
- the active ingredients used are chosen from a wide variety of therapeutic and prophylactic compounds. They are more particularly chosen from proteins and peptides such as insulin, calcitonin, analogs of the hormone LH-RH, polysaccharides such as heparin, anti-asthmatics such as budesonide, dipropionate of beclometasone and its active metabolite
- FIG. 1 is a photograph by electron microscopy of a microparticle obtained according to example 2.
- FIG. 2 is a photograph by electron microscopy of microparticles obtained according to example 3.
- the examples which follow illustrate the invention without limiting its scope.
- This example illustrates the first method of implementing the invention.
- the CO 2 in the liquid state mixes with the suspension thus making it possible to wet the insulin, and also making it possible to ensure the progressive precipitation of the coating agent.
- the CO 2 is passed to the supercritical state by gradually increasing the pressure to 150 10 5 Pa.
- the temperature is jointly maintained at 40 ° C.
- ethyl acetate is extracted.
- These conditions are maintained for 15 minutes, then the CO 2 / ethyl acetate mixture is removed by decompressing up to 75 ⁇ 10 5 Pa in a separator while maintaining the temperature at a value greater than 35 ° C.
- the ethyl acetate is recovered in this separator and the CO 2 returns to a tank.
- the ethyl acetate is recovered and the successive cycles of introduction of liquid CO 2 , transition to the supercritical state and evacuation of CO 2 + ethyl acetate are repeated until complete elimination of the acetate ethyl.
- the decompression is necessarily done by the gas phase so as not to reconcentrate coating agent in the remaining ethyl acetate.
- the operation can be repeated several times by reintroducing CO 2 in order to find a pressure of 150 10 5 Pa and a temperature of 40 ° C.
- the temperature in this case is generally between 35 and 45 ° C. and the pressure between 180 and 220 ⁇ 10 5 Pa. This gives 250 mg of non-aggregated microparticles with an average size of 3 ⁇ m and comprising 80 to 90% by weight of insulin, which have improved nebulizing properties.
- This example illustrates the second method of implementing the invention.
- BSA bovine serum albumin
- CO 2 is introduced into the autoclave, up to a pressure of 95 10 5 Pa at a temperature of 25 ° C. The CO 2 is then in the liquid state.
- the weight ratio active ingredient / coating agent is about 30/70.
- This example illustrates the second method of implementing the invention.
- OVA ovalbumin
- CO 2 is introduced into the autoclave, up to a pressure of 109
- the stirring is started, and fixed at 340 rpm. Then the autoclave is heated to 35 ° C. The pressure is then 180 10 5 Pa, the CO 2 is in the supercritical state. The system is allowed to balance for one hour. The temperature of the autoclave is then lowered to 16 ° C. for a period of 43 minutes starting from 35 ° C. The phase suspended in supercritical CO 2 is thus transformed into a mixture of liquid and gaseous CO 2 .
- This example illustrates the second method of implementing the invention.
- 300 mg of beclomethasone dipropionate in the form of a loose powder prepared by atomization and 50 mg of Dilauroyl Phosphatidyl Glycerol (DLPG) are placed in a 0.3 I pressurizable autoclave fitted with a porous insert.
- DLPG Dilauroyl Phosphatidyl Glycerol
- CO 2 is introduced into the autoclave, up to a pressure of 98 10 5 Pa for a temperature of 23 ° C. The CO 2 is then in the liquid state.
- the system is allowed to balance for one hour.
- the temperature of the autoclave is then lowered to 20 ° C for a period of 65 minutes.
- the phase in suspension in supercritical CO 2 thus transforms into a mixture of liquid and gaseous CO 2 , the particles of active principle being in suspension in liquid CO 2 .
- microparticles of beclomethasone dipropionate coated with DLPG are obtained.
- DLPG whose active ingredient / coating agent mass ratio is approximately 90/10. These microparticles have improved nebulization properties.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9910411A FR2797398B1 (fr) | 1999-08-11 | 1999-08-11 | Microparticules pour administration pulmonaire |
FR9910411 | 1999-08-11 | ||
PCT/FR2000/002282 WO2001012160A1 (fr) | 1999-08-11 | 2000-08-09 | Microparticules pour administration pulmonaire |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1204409A1 true EP1204409A1 (fr) | 2002-05-15 |
Family
ID=9549086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00958655A Withdrawn EP1204409A1 (fr) | 1999-08-11 | 2000-08-09 | Microparticules pour administration pulmonaire |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1204409A1 (fr) |
JP (1) | JP2003506479A (fr) |
KR (1) | KR20020038719A (fr) |
CN (1) | CN1220484C (fr) |
AU (1) | AU784168B2 (fr) |
CA (1) | CA2380883A1 (fr) |
FR (1) | FR2797398B1 (fr) |
HU (1) | HUP0202545A3 (fr) |
IL (1) | IL148063A0 (fr) |
MX (1) | MXPA02001520A (fr) |
NO (1) | NO20020555L (fr) |
WO (1) | WO2001012160A1 (fr) |
ZA (1) | ZA200201109B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2809309B1 (fr) * | 2000-05-23 | 2004-06-11 | Mainelab | Microspheres a liberation prolongee pour administration injectable |
EP1486204A1 (fr) * | 2002-03-18 | 2004-12-15 | Yamanouchi Pharmaceutical Co. Ltd. | Compositions medicales en poudre pour inhalation et procede de production de celles-ci |
JP2005279334A (ja) * | 2004-03-26 | 2005-10-13 | Kao Corp | 複合化粒子の製造方法 |
WO2007009164A1 (fr) | 2005-07-15 | 2007-01-25 | Eiffel Technologies Limited | Procede de formation de particules |
EP1757361A1 (fr) * | 2005-08-23 | 2007-02-28 | Feyecon Development & Implementation B.V. | Procédé de préparation d'encapsulations par précipitation |
CN101143131B (zh) * | 2006-09-15 | 2012-03-07 | 国家纳米技术与工程研究院 | 一种利用超临界流体技术制备人胰岛素吸入干粉的方法 |
CA2664311C (fr) * | 2006-09-15 | 2015-08-18 | Echo Pharmaceuticals B.V. | Granulat contenant une substance pharmaceutiquement active et son procede de fabrication |
CA2681308C (fr) * | 2007-03-23 | 2015-11-24 | Geno Llc | Conversion du dioxyde d'azote (no<sb>2</sb>) en oxyde nitrique (no) |
KR101102834B1 (ko) | 2010-02-24 | 2012-01-05 | 충남대학교산학협력단 | 신규한 리포좀 제조 방법 및 장치 |
JP5672554B2 (ja) * | 2010-08-19 | 2015-02-18 | Jcrファーマ株式会社 | 皮下又は経皮吸収用組成物 |
CN102872027B (zh) * | 2012-09-18 | 2014-03-12 | 刘晓忠 | 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04222662A (ja) * | 1990-12-25 | 1992-08-12 | Nippon Steel Chem Co Ltd | 固体表面へのポリマー皮膜形成方法 |
EP0706821A1 (fr) * | 1994-10-06 | 1996-04-17 | Centre De Microencapsulation | Procédé pour l'enrobage de particules |
ATE212545T1 (de) * | 1995-03-28 | 2002-02-15 | Fidia Advanced Biopolymers Srl | Nanosphären mit einem biokompatiblen polysaccharid |
FR2753639B1 (fr) * | 1996-09-25 | 1998-12-11 | Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede | |
US5766637A (en) * | 1996-10-08 | 1998-06-16 | University Of Delaware | Microencapsulation process using supercritical fluids |
CA2277801C (fr) * | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation de particules pour inhalation |
JPH1147681A (ja) * | 1997-08-05 | 1999-02-23 | Kira Keshohin Kk | 超臨界流体を用いた微粒子のコーティング方法及び塗装物 |
JPH11197494A (ja) * | 1998-01-13 | 1999-07-27 | Kenji Mishima | 超臨界流体を用いた微小粒子コーティング |
-
1999
- 1999-08-11 FR FR9910411A patent/FR2797398B1/fr not_active Expired - Lifetime
-
2000
- 2000-08-09 IL IL14806300A patent/IL148063A0/xx unknown
- 2000-08-09 AU AU70104/00A patent/AU784168B2/en not_active Ceased
- 2000-08-09 CN CNB008116660A patent/CN1220484C/zh not_active Expired - Fee Related
- 2000-08-09 KR KR1020027001717A patent/KR20020038719A/ko not_active Application Discontinuation
- 2000-08-09 EP EP00958655A patent/EP1204409A1/fr not_active Withdrawn
- 2000-08-09 WO PCT/FR2000/002282 patent/WO2001012160A1/fr not_active Application Discontinuation
- 2000-08-09 CA CA002380883A patent/CA2380883A1/fr not_active Abandoned
- 2000-08-09 HU HU0202545A patent/HUP0202545A3/hu unknown
- 2000-08-09 MX MXPA02001520A patent/MXPA02001520A/es active IP Right Grant
- 2000-08-09 JP JP2001516507A patent/JP2003506479A/ja active Pending
-
2002
- 2002-02-04 NO NO20020555A patent/NO20020555L/no not_active Application Discontinuation
- 2002-02-08 ZA ZA200201109A patent/ZA200201109B/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0112160A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU784168B2 (en) | 2006-02-16 |
FR2797398A1 (fr) | 2001-02-16 |
CN1461211A (zh) | 2003-12-10 |
ZA200201109B (en) | 2002-10-30 |
CA2380883A1 (fr) | 2001-02-22 |
AU7010400A (en) | 2001-03-13 |
MXPA02001520A (es) | 2003-07-21 |
FR2797398B1 (fr) | 2002-10-18 |
HUP0202545A2 (hu) | 2004-03-01 |
WO2001012160A1 (fr) | 2001-02-22 |
NO20020555L (no) | 2002-04-09 |
KR20020038719A (ko) | 2002-05-23 |
NO20020555D0 (no) | 2002-02-04 |
HUP0202545A3 (en) | 2004-05-28 |
JP2003506479A (ja) | 2003-02-18 |
IL148063A0 (en) | 2002-09-12 |
CN1220484C (zh) | 2005-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101511196B1 (ko) | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법 | |
CA2294981C (fr) | Nouvelles formulations d'agents pharmacologiques, leurs procedes de preparation et d'utilisation | |
US20150111960A1 (en) | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof | |
FR2754453A1 (fr) | Preparations pharmaceutiques a administrer par voie nasale | |
LU88087A1 (fr) | Forme pharmaceutique de cyclosporine pour administration par voie pulmonaire | |
US20040105821A1 (en) | Sustained release pharmaceutical formulation for inhalation | |
Bi et al. | Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery | |
KR20030063117A (ko) | 많은 치료학적 양의 에어로졸을 효과적으로 전달하는 방법 | |
JP2001507701A (ja) | 親水性賦形剤を有する疎水性薬剤の溶液を噴霧乾燥するための方法及びその方法によって作製された組成物 | |
TW201109050A (en) | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting β2 adrenergic receptor agonists and associated methods and systems | |
EP1204409A1 (fr) | Microparticules pour administration pulmonaire | |
FR2702968A1 (fr) | Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation . | |
JP2010508256A (ja) | 加圧型用量計量吸引器による送達のための処方剤 | |
EP1333812A1 (fr) | Microgranules a base de principe actif et leur procede de fabrication | |
WO1998056352A1 (fr) | Nouveaux vecteurs liposomaux de principes actifs | |
CA2562495C (fr) | Utilisation de dipalmitostearate de glycerol pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous-cutanees ou intramusculaires | |
Miyazaki et al. | Improved respirable fraction of budesonide powder for dry powder inhaler formulations produced by advanced supercritical CO2 processing and use of a novel additive | |
JP2007533694A (ja) | 乾燥粉末医薬組成物、その製造方法、およびその組成物から得られる安定な水性懸濁液 | |
FR2967066A1 (fr) | Utilisation par voie sublinguale de microgranules non comprimes | |
CA2477592A1 (fr) | Compositions medicales en poudre pour inhalation et procede de production de celles-ci | |
FR2758265A1 (fr) | Microspheres effervescentes et leur procede de fabrication | |
CA2765222C (fr) | Nouvelles formulations d'agents pharmacologiques, leurs procedes de preparation et d'utilisation | |
FR3130554A1 (fr) | Composition pharmaceutique comprenant du salbutamol | |
EP4051249A1 (fr) | Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing | |
FR2742659A1 (fr) | Procede de fabrication de minispheres matricielles a liberation prolongee |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20020225;LT PAYMENT 20020225;LV PAYMENT 20020225;MK PAYMENT 20020225;RO PAYMENT 20020225;SI PAYMENT 20020225 |
|
17Q | First examination report despatched |
Effective date: 20040413 |
|
17Q | First examination report despatched |
Effective date: 20040413 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: USE OF MICROPARTICLES FOR PULMONARY ADMINISTRATION |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080103 |